步长制药
(603858)
| 流通市值：166.73亿 | | | 总市值：166.73亿 |
| 流通股本：10.55亿 | | | 总股本：10.55亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,579,013,525.28 | 11,875,013,010.12 | 8,468,581,319.22 | 5,663,836,253.89 |
| 营业收入 | 2,579,013,525.28 | 11,875,013,010.12 | 8,468,581,319.22 | 5,663,836,253.89 |
| 二、营业总成本 | 2,180,656,976.18 | 10,600,810,736.07 | 7,531,602,618.43 | 4,990,838,810.29 |
| 营业成本 | 945,267,292.76 | 4,399,990,372.09 | 3,192,193,227.23 | 2,130,994,967.96 |
| 税金及附加 | 38,530,950.52 | 176,006,501.14 | 125,709,791.24 | 84,252,129.22 |
| 销售费用 | 946,410,381.21 | 4,828,332,232.54 | 3,341,254,788.63 | 2,239,340,547.33 |
| 管理费用 | 179,721,159.7 | 843,025,161.72 | 633,582,140.13 | 394,727,994.4 |
| 研发费用 | 42,834,669.61 | 240,102,458.57 | 153,627,979.11 | 84,196,636.41 |
| 财务费用 | 27,892,522.38 | 113,354,010.01 | 85,234,692.09 | 57,326,534.97 |
| 其中:利息费用 | 28,722,255.25 | 118,700,545.2 | 88,586,777.48 | 59,869,654.26 |
| 其中:利息收入 | 786,691.73 | 4,836,847.23 | 4,190,242.96 | 3,148,463.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -2,396,282.88 | -279,493,363.52 | 13,706,548.91 | 3,377,528.63 |
| 加:投资收益 | -17,905,331.12 | -3,840,753.16 | 5,342,536.48 | 4,570,467.9 |
| 资产处置收益 | 285,576.44 | 156,484.37 | 152,441.02 | 157,220.65 |
| 资产减值损失(新) | 662,841.55 | -527,219,503.79 | -8,355,874.39 | 2,601,071.04 |
| 信用减值损失(新) | -7,135,038.07 | 14,347,948.32 | 31,954,870.19 | 34,276,981.07 |
| 其他收益 | 13,957,474.39 | 87,955,649.28 | 69,322,635.29 | 49,767,597.12 |
| 四、营业利润 | 385,825,789.41 | 566,108,735.55 | 1,049,101,858.29 | 767,748,310.01 |
| 加:营业外收入 | 702,824.28 | 4,967,765.31 | 3,214,964.97 | 1,727,186.77 |
| 减:营业外支出 | 3,947,193.54 | 37,121,029.15 | 31,737,779.7 | 19,883,951.03 |
| 五、利润总额 | 382,581,420.15 | 533,955,471.71 | 1,020,579,043.56 | 749,591,545.75 |
| 减:所得税费用 | 79,478,670.97 | 341,657,918.23 | 229,450,624.66 | 159,362,361.9 |
| 六、净利润 | 303,102,749.18 | 192,297,553.48 | 791,128,418.9 | 590,229,183.85 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 303,102,749.18 | 192,297,553.48 | 791,128,418.9 | 590,229,183.85 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 320,411,354.85 | 360,784,856.21 | 868,323,718.42 | 627,701,257.33 |
| 少数股东损益 | -17,308,605.67 | -168,487,302.73 | -77,195,299.52 | -37,472,073.48 |
| 扣除非经常损益后的净利润 | 310,186,180.17 | 634,750,809.03 | 855,105,661.35 | 618,837,568.16 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.3 | 0.34 | 0.82 | 0.59 |
| (二)稀释每股收益 | 0.3 | 0.34 | 0.82 | 0.59 |
| 八、其他综合收益 | 6,756,134.75 | -53,165,050.17 | -50,998.71 | 312,653.69 |
| 归属于母公司股东的其他综合收益 | 6,756,134.75 | -53,165,050.17 | -50,998.71 | 312,653.69 |
| 九、综合收益总额 | 309,858,883.93 | 139,132,503.31 | 791,077,420.19 | 590,541,837.54 |
| 归属于母公司股东的综合收益总额 | 327,167,489.6 | 307,619,806.04 | 868,272,719.71 | 628,013,911.02 |
| 归属于少数股东的综合收益总额 | -17,308,605.67 | -168,487,302.73 | -77,195,299.52 | -37,472,073.48 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-30 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |